Sutro Biopharma (NASDAQ:STRO) Issues Earnings Results

Sutro Biopharma (NASDAQ:STRO) posted its quarterly earnings results on Thursday. The company reported ($2.96) earnings per share for the quarter, RTT News reports. Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. During the same period in the prior year, the firm posted ($1.78) earnings per share.

Sutro Biopharma Stock Performance

STRO opened at $1.25 on Friday. The firm has a market cap of $103.07 million, a P/E ratio of -0.78 and a beta of 1.22. Sutro Biopharma has a 52-week low of $1.25 and a 52-week high of $6.13. The business’s fifty day moving average is $1.79 and its 200-day moving average is $2.79.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on STRO shares. JMP Securities restated a “market outperform” rating and issued a $17.00 price target on shares of Sutro Biopharma in a research note on Wednesday, December 11th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Sutro Biopharma in a research note on Monday, November 18th. Wells Fargo & Company dropped their price target on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Finally, Wedbush reiterated an “outperform” rating and set a $8.00 price objective on shares of Sutro Biopharma in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.13.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.